Witryna28 maj 2024 · We report the primary disease-free survival (DFS) results from the pre-planned interim analysis of IMpower010, a randomized phase 3 open-label trial of … Witryna28 wrz 2024 · Like the IMpower133 study, this study met its primary end point with an improvement in OS in the durvalumab-plus-chemotherapy arm with a margin of 2 months and a near identical hazard ratio of 0.75, which is very similar to the IMpower133 study. At 2 years, 22% of patients were alive in the immunotherapy arm vs 14% in the …
A Study of Carboplatin Plus Etoposide With or Without …
WitrynaIMpower133 (NCT02763579), a global phase I/III, double-blind, randomized, placebo-controlled trial, showed that adding atezo (anti–PD-L1) to 1L carboplatin + etoposide … WitrynaIMpower110 is a global, randomized, open-label, phase 3 trial designed to evaluate the efficacy and safety of atezolizumab as compared with platinum-based chemotherapy … ontario subway line map
IMpower131: Final Overall Survival Results of Carboplatin + Nab ...
Witryna2 cze 2024 · The 1,280-patient IMpower010 study compared adjuvant Tecentriq to BSC in patients with Stage IB–IIIA NSCLC. Data in the all-comers population of Stage IB–IIIA is not yet mature, while the efficacy based on patient subgroups was not provided in … WitrynaEMPOWER-Lung 3 is a randomised, 2-part, Phase 3 study of 1L treatment of patients (pts) with advanced (Stage III/IV) squamous (SQ) or non-squamous (NSQ) NSCLC without actionable mutations (NCT03409614). Witryna19 lut 2015 · This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve … ionic compounds lewis structure